ERBB2 and invasive breast carcinoma: On comparison based on characteristics and clinical behavior, HER2 positive (HER2+) DCIS are considered more violent thanany other DCIS subtypes and studied as a potential biomarker for progression to invasive breast carcinomas whereas at cellular level CD44/CD24, N-cadherin/E-cadherin and CD74/CD59were reported as the biomarker pairs for specifically in DCIS cases [15-17].